Kenneth Bo Pedersen

Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases

J. Seidelin, P. Munkholm, A. Popa, 2021, Scandinavian journal of gastroenterology.